Literature DB >> 15320855

Antiproliferative strategies for the treatment of vascular proliferative disease.

Vicente Andrés1, Claudia Castro.   

Abstract

Excessive cellular proliferation contributes to the pathobiology of vascular obstructive diseases (e.g., atherosclerosis, in-stent restenosis, transplant vasculopathy, and vessel bypass graft failure). Therefore, anti-proliferative therapies may be a suitable approach in the treatment of these disorders. Candidate targets for such strategies include the cyclin-dependent kinase/cyclin holoenzymes, members of the cyclin-dependent kinase family of inhibitory proteins, tumor suppressors, growth factors and transcription factors that control cell cycle progression. In this review, we will discuss the use of pharmacological agents and gene therapy approaches targeting cellular proliferation in animal models and clinical trials of cardiovascular disease.

Entities:  

Mesh:

Year:  2003        PMID: 15320855     DOI: 10.2174/1570161033386763

Source DB:  PubMed          Journal:  Curr Vasc Pharmacol        ISSN: 1570-1611            Impact factor:   2.719


  9 in total

1.  Valsartan inhibits angiotensin II-induced proliferation of vascular smooth muscle cells via regulating the expression of mitofusin 2.

Authors:  Hua Liao; Junrong Gong; Wenjuan Zhang; Xiaomei Guo
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2012-01-27

Review 2.  Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.

Authors:  Larissa Lipskaia; Lahouaria Hadri; Jose J Lopez; Roger J Hajjar; Regis Bobe
Journal:  Curr Vasc Pharmacol       Date:  2013-07       Impact factor: 2.719

3.  Activatory properties of lysophosphatidic acid on human THP-1 cells.

Authors:  F D'Aquilio; M Procaccini; V Izzi; V Chiurchiu'; V Giambra; F Carotenuto; P Di Nardo; P M Baldini
Journal:  Inflammation       Date:  2006-11-07       Impact factor: 4.092

4.  Involvement of estrogen receptor-β in farrerol inhibition of rat thoracic aorta vascular smooth muscle cell proliferation.

Authors:  Qun-yi Li; Li Chen; Yan-hui Zhu; Meng Zhang; Yi-ping Wang; Ming-wei Wang
Journal:  Acta Pharmacol Sin       Date:  2011-03-14       Impact factor: 6.150

5.  Trichostatin A enhances proliferation and migration of vascular smooth muscle cells by downregulating thioredoxin 1.

Authors:  Seungjeong Song; Sang Won Kang; Chulhee Choi
Journal:  Cardiovasc Res       Date:  2010-01-01       Impact factor: 10.787

6.  Activatory properties of lysophosphatidic acid on human THP-1 cells.

Authors:  F D'Aquilio; M Procaccini; V Izzi; V Chiurchiu'; V Giambra; F Carotenuto; P Di Nardo; P M Baldini
Journal:  Inflammation       Date:  2007-10       Impact factor: 4.092

7.  Modulating the functional contributions of c-Myc to the human endothelial cell cyclic strain response.

Authors:  Nicole E Hurley; Lisa A Schildmeyer; Kami A Bosworth; Yumiko Sakurai; Suzanne G Eskin; Laurence H Hurley; Larry V McIntire
Journal:  J Vasc Res       Date:  2009-09-03       Impact factor: 1.934

8.  Thiamylal sodium increased inflammation and the proliferation of vascular smooth muscle cells.

Authors:  Ryohei Miyazaki; Sumio Hoka
Journal:  Korean J Anesthesiol       Date:  2016-06-01

9.  Docosahexaenoic Acid Inhibits Vascular Smooth Muscle Cell Proliferation Induced by Glucose Variability.

Authors:  Kaliyaperumal Rani; Nway Y Aung
Journal:  Open Biochem J       Date:  2017-06-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.